Cyclarity
Novato, US · Founded 2019 · 19 employees on LinkedIn · 1 known investors
Cyclarity Therapeutics develops drugs based on cyclodextrin derivatives to treat atherosclerosis by removing arterial plaque, targeting the non-degradable cholesterol that accumulates in arterial wall cells. The company aims to provide a preventive therapy for age-related cardiovascular conditions such as heart attack and stroke.
Founders & leadership
Cyclarity was founded in 2019 by Matthew O'Connor.
MO
Matthew O'ConnorFounder
MK
Michael KopeNamed on SEC filing
FS
Frank SchuelerNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$15.3M disclosed across 3 rounds · 2019–2024
▶$10.3MraisedDec 2024 · 19 investors · PharmaceuticalsRule 506(b)
▶$10.3MraisedDec 2024 · 19 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Matthew O'ConnorExecutive Officer, Director
- Michael KopeExecutive Officer, Director
- Offering amount
- $12.8M
- Amount sold
- $10.3M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedSep 2021 · 10 investors · PharmaceuticalsRule 506(b)
▶$3.5MraisedSep 2021 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Matthew O'ConnorExecutive Officer, Director
- Frank SchuelerDirector
- Michael KopeExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $3.5M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.5MraisedNov 2019 · 9 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedNov 2019 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Matthew O'ConnorExecutive Officer, Director
- Frank SchuelerDirector
- Michael KopeExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $1.5M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Cyclarity do?
- Cyclarity Therapeutics develops drugs based on cyclodextrin derivatives to treat atherosclerosis by removing arterial plaque, targeting the non-degradable cholesterol that accumulates in arterial wall cells. The company aims to provide a preventive therapy for age-related cardiovascular conditions such as heart attack and stroke.
- Who founded Cyclarity?
- Cyclarity was founded by Matthew O'Connor in 2019.
- Who are Cyclarity's investors?
- Cyclarity's investors include Seed Healthcare.
- How much funding has Cyclarity raised?
- Cyclarity has disclosed $15.3M raised across 3 rounds.
- Where is Cyclarity headquartered?
- Cyclarity is headquartered in Novato, US.